Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2460604 | 0.81 | ACHE (0.40) | CES2CES1 | |
| SCHEMBL777916 | 0.81 | CES2 (0.38) | CES2CES1BCHEHPGDHTR2C | |
| SCHEMBL23569368 | 0.78 | NR4A2 (0.34) | — | |
| SCHEMBL23531754 | 0.78 | NR4A2 (0.34) | — | |
| SCHEMBL777108 | 0.77 | CES2 (0.35) | CES2CES1BCHEHPGD | |
| SCHEMBL23912724 | 0.77 | CES2 (0.35) | CES2CES1BCHEHPGD | |
| SCHEMBL6874177 | 0.77 | CES2 (0.35) | CES2CES1BCHEHPGD | |
| SCHEMBL23568538 | 0.73 | CES2 (0.33) | CES2CES1BCHE | |
| SCHEMBL778509 | 0.72 | CES2 (0.32) | CES2CES1BCHE | |
| SCHEMBL14647402 | 0.72 | BACE1 (0.33) | CES2CES1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802110-B2 | 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase | Oxford Drug Design Limited (GB) | 2023-10-31 | — | — | US | disclosed |
| US-11802110-B2 | 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase | Oxford Drug Design Limited (GB) | 2023-10-31 | — | — | US | disclosed |
| US-20200039929-A1 | 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE | INHIBOX LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| WO-2018065611-A1 | 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE | Oxford Drug Design Limited (GB) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802110-B2 | 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase | AARS1, NSUN3, GARS1 | CES2 1372/4885CES1 1245/4885BCHE 2921/4885 |
| US-20200039929-A1 | 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE | AARS1, NSUN3, GARS1 | CES2 1372/4885CES1 1245/4885BCHE 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.